Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma

Current Medicinal Chemistry

Volumn 18, Issue 28, 2011, Pages 4375-4388

  Sato, K ^a   Mori, M ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell signaling; Clinical trials; Combination therapy; Efficacy; Hepatocellular carcinoma; Molecular carcinogenesis; Molecular targets; Molecularly targeted agents; Preclinical studies; Safety

Indexed keywords

BEVACIZUMAB; BRIVANIB ALANINATE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; IMATINIB; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; OCTREOTIDE; OXALIPLATIN; PERETINOIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN RECEPTOR; SORAFENIB; STAT PROTEIN; SUNITINIB; TARCEBA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ALBUMINURIA; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; APHTHOUS STOMATITIS; APOPTOSIS; ASTHENIA; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; FATIGUE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; ISCHEMIA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MOLECULAR MECHANICS; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; THROMBOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LIVER NEOPLASMS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 80052926787     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797200462     Document Type: Review

References (192)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA. Cancer J. Clin., 2005, 55(2), 74-108.
2. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
3. Spangenberg, H.C.; Thimme, R.; Blum, H.E. Targeted therapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol., 2009, 6(7), 423-432.
4. Huynh, H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem. Pharmacol., 2010, 80(5), 550-560.
5. Llovet, J.M.; Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48(4), 1312-1327.
6. Kudo, M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int. J. Clin. Oncol., 2010, 15(3), 242-255.
7. Baselga, J.; Arteaga, C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol., 2005, 23(11), 2445-2459. (Pubitemid 47050835)
8. Sato, Y.; Kato, J.; Takimoto, R.; Takada, K.; Kawano, Y.; Miyanishi, K.; Kobune, M.; Takayama, T.; Matunaga, T.; Niitsu, Y. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut, 2006, 55(12), 1801-1808. (Pubitemid 44893582)
9. Harada, K.; Shiota, G.; Kawasaki, H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver, 1999, 19(4), 318-325. (Pubitemid 29359097)
10. Hisaka, T.; Yano, H.; Haramaki, M.; Utsunomiya, I.; Kojiro, M. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int. J. Oncol., 1999, 14(3), 453-460.
11. Ito, Y.; Takeda, T.; Higashiyama, S.; Sakon, M.; Wakasa, K.I.; Tsujimoto, M.; Monden, M.; Matsuura, N. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol. Rep., 2001, 8(4), 903-907. (Pubitemid 33758146)
12. Miura, H.; Miyazaki, T.; Kuroda, M.; Oka, T.; Machinami, R.; Kodama, T.; Shibuya, M.; Makuuchi, M.; Yazaki, Y.; Ohnishi, S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol., 1997, 27(5), 854-861. (Pubitemid 27454829)
13. Torimura, T.; Sata, M.; Ueno, T.; Kin, M.; Tsuji, R.; Suzaku, K.; Hashimoto, O.; Sugawara, H.; Tanikawa, K. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum. Pathol., 1998, 29(9), 986-991. (Pubitemid 28422048)
14. Poon, R.T.; Ng, I.O.; Lau, C.; Yu, W.C.; Fan, S.T.; Wong, J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. J. Surg., 2001, 182(3), 298-304. (Pubitemid 32918381)
15. Tanaka, S.; Sugimachi, K.; Yamashita Yi.Y.; Ohga, T.; Shirabe, K.; Shimada, M.; Wands, J.R.; Sugimachi K. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology, 2002, 35(4), 861-867. (Pubitemid 34258380)
16. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol., 2006, 39(5), 469-478. (Pubitemid 44714526)
17. Ng, I.O.; Poon, R.T.; Lee, J.M.; Fan, S.T.; Ng, M.; Tso, W.K. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol., 2001, 116(6), 838-845. (Pubitemid 33108154)
18. Li, X.M.; Tang, Z.Y.; Zhou, G.; Lui, Y.K.; Ye, S.L. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res., 1998, 17(1), 13-17. (Pubitemid 28215959)
19. El-Assal, O.N.; Yamanoi, A.; Soda, Y.; Yamaguchi, M.; Igarashi, M.; Yamamoto, A.; Nabika, T.; Nagasue, N. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology, 1998, 27(6), 1554-1562. (Pubitemid 28264678)
20. Li, X.; Eriksson, U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev., 2003, 14(2), 91-98. (Pubitemid 36389523)
21. Conway, E.M.; Collen, D.; Carmeliet, P. Molecular mechanisms of blood vessel growth. Cardiovasc. Res., 2001, 49(3), 507-521. (Pubitemid 32146414)
22. Dirks, R.P.; Bloemers, H.P. Signals controlling the expression of PDGF. Mol. Biol. Rep., 1995, 22(1), 1-24. (Pubitemid 26351656)
23. Heldin, C.H.; Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev., 1999, 79(4), 1283-1316. (Pubitemid 29473317)
24. Alvarez, R.H.; Kantarjian, H.M.; Cortes, J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin. Proc., 2006, 81(9), 1241-1257. (Pubitemid 44316290)
25. Campbell, J.S.; Hughes, S.D.; Gilbertson, D.G.; Palmer, T.E.; Holdren, M.S.; Haran, A.C.; Odell, M.M.; Bauer, R.L.; Ren, H.P.; Haugen, H.S.; Yeh, M.M.; Fausto, N. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(9), 3389-3394. (Pubitemid 40328055)
26. Maass, T.; Thieringer, F.R.; Mann, A.; Longerich, T.; Schirmacher, P.; Strand, D.; Hansen, T.; Galle, P.R.; Teufel, A.; Kanzler, S. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int. J. Cancer, 2011, 128(6), 1259-1268.
27. Tsou, A.P.; Wu, K.M.; Tsen, T.Y.; Chi, C.W.; Chiu, J.H.; Lui, W.Y.; Hu, C.P.; Chang, C.; Chou, C.K.; Tsai, S.F. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics, 1998, 50(3), 331-340. (Pubitemid 28328753)
28. Breitkopf, K.; Roeyen, C.; Sawitza, I.; Wickert, L.; Floege, J.; Gressner, A.M. Expression patterns of PDGF-A, -B, -C and -D and the PDGFreceptors alpha and beta in activated rat hepatic stellate cells (HSC). Cytokine, 2005, 31(5), 349-357. (Pubitemid 41188056)
29. Zhang, T.; Sun, H.C.; Xu, Y.; Zhang, K.Z.; Wang, L.; Qin, L.X.; Wu, W.Z.; Liu, Y.K.; Ye, S.L.; Tang, Z.Y. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin. Cancer Res., 2005, 11(24 Pt 1), 8557-8563. (Pubitemid 43005900)
30. Johnson, D.E.; Williams, L.T. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res., 1993, 60, 1-41.
31. Yayon, A.; Klagsbrun, M.; Esko, J.D.; Leder, P.; Ornitz, D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell, 1991, 64(4), 841-848. (Pubitemid 121001170)
32. Ornitz, D.M.; Yayon, A.; Flanagan, J.G.; Svahn, C.M.; Levi, E.; Leder, P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol. Cell Biol., 1992, 12(1), 240-247.
33. Flaumenhaft, R.; Rifkin, D.B. The extracellular regulation of growth factor action. Mol. Biol. Cell, 1992, 3(10), 1057-1065. (Pubitemid 23088956)
34. Kato, M.; Wang, H.; Kainulainen, V.; Fitzgerald, M.L.; Ledbetter, S.; Ornitz, D.M.; Bernfield, M. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med., 1998, 4(6), 691-697. (Pubitemid 28274669)
35. El-Assal, O.N.; Yamanoi, A.; Ono, T.; Kohno, H.; Nagasue, N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin. Cancer Res., 2001, 7(5), 1299-1305. (Pubitemid 32708684)
36. Bikfalvi, A.; Klein, S.; Pintucci, G.; Rifkin, D.B. Biological roles of fibroblast growth factor-2. Endocr. Rev., 1997, 18(1), 26-45. (Pubitemid 27076454)
37. Stavri, G.T.; Zachary, I.C.; Baskerville, P.A.; Martin, J.F.; Erusalimsky, J.D. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation, 1995, 92(1), 11-14.
38. Asahara, T.; Bauters, C.; Zheng, L.P.; Takeshita, S.; Bunting, S.; Ferrara, N.; Symes, J.F.; Isner, J.M. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation, 1995, 92(9 Suppl), II365-II371.
39. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D.J.; Huber, J.; Nakatani, T.; Tsujinoue, H.; Yanase, K.; Imazu, H.; Fukui, H. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology, 2002, 35(4), 834-842. (Pubitemid 34258377)
40. Pollak, M.N.; Schernhammer, E.S.; Hankinson, S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer, 2004, 4(7), 505-518. (Pubitemid 38868620)
41. Scharf, J.G.; Braulke, T. The role of the IGF axis in hepatocarcinogenesis. Horm. Metab. Res., 2003, 35(11-12), 685-693. (Pubitemid 38058172)
42. Breuhahn, K.; Longerich, T.; Schirmacher, P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene, 2006, 25(27), 3787-3800. (Pubitemid 43980474)
43. Tanaka, S.; Mohr, L.; Schmidt, E.V.; Sugimachi, K.; Wands, J.R. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology, 1997, 26(3), 598-604. (Pubitemid 27392349)
44. Tanaka, S.; Wands, J.R. A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J. Clin. Invest., 1996, 98(9), 2100-2108. (Pubitemid 26376299)
45. Alexia, C.; Fallot, G.; Lasfer, M.; Schweizer-Groyer, G.; Groyer, A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem. Pharmacol., 2004, 68(6), 1003-1015. (Pubitemid 39094263)
46. Yu, H.; Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst., 2000, 92(18), 1472-1489.
47. Fausto, N.; Campbell, J.S.; Riehle, K.J. Liver regeneration. Hepatology, 2006, 43(2 Suppl 1), S45-S53.
48. Kaposi-Novak, P.; Lee, J.S.; Gomez-Quiroz, L.; Coulouarn, C.; Factor, V.M.; Thorgeirsson, S.S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest., 2006, 116(6), 1582-1595.
49. Osada, S.; Kanematsu, M.; Imai, H.; Goshima, S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology, 2008, 55(82-83), 544-549. (Pubitemid 351741499)
50. Park, W.S.; Dong, S.M.; Kim, S.Y.; Na, E.Y.; Shin, M.S.; Pi, J.H.; Kim, B.J.; Bae, J.H.; Hong, Y.K.; Lee, K.S.; Lee, S.H.; Yoo, N.J.; Jang, J.J.; Pack, S.; Zhuang, Z.; Schmidt, L.; Zbar, B.; Lee, J.Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res., 1999, 59(2), 307-310. (Pubitemid 29048858)
51. Villanueva, A.; Newell, P.; Chiang, D.Y.; Friedman, S.L.; Llovet, J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis., 2007, 27(1), 55-76.
52. Takami, T.; Kaposi-Novak, P.; Uchida, K.; Gomez-Quiroz, L.E.; Conner, E.A.; Factor, V.M.; Thorgeirsson, S.S. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res., 2007, 67(20), 9844-9851. (Pubitemid 47621232)
53. Huynh, H. Tyrosine kinase inhibitors to treat liver cancer. Expert. Opin. Emerg. Drugs, 2010, 15(1), 13-26.
54. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2(7), 489-501. (Pubitemid 37328931)
55. Sabatini, D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer, 2006, 6(9), 729-734. (Pubitemid 44286004)
56. Schmitz, K.J.; Wohlschlaeger, J.; Lang, H.; Sotiropoulos, G.C.; Malago, M.; Steveling, K.; Reis, H.; Cicinnati, V.R.; Schmid, K.W.; Baba, H.A. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol., 2008, 48(1), 83-90. (Pubitemid 350191996)
57. Boyault, S.; Rickman, D.S.; de Reynies, A.; Balabaud, C.; Rebouissou, S.; Jeannot, E.; Herault, A.; Saric, J.; Belghiti, J.; Franco, D.; Bioulac-Sage, P.; Laurent-Puig, P.; Zucman-Rossi, J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 2007, 45(1), 42-52. (Pubitemid 46144363)
58. Huynh, H.; Chow, P.K.; Palanisamy, N.; Salto-Tellez, M.; Goh, B.C.; Lee, C.K.; Somani, A.; Lee, H.S.; Kalpana, R.; Yu, K.; Tan, P.H.; Wu, J.; Soong, R.; Lee, M.H.; Hor, H.; Soo, K.C.; Toh, H.C.; Tan, P. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J. Hepatol., 2008, 49(1), 52-60.
59. Sahin, F.; Kannangai, R.; Adegbola, O.; Wang, J.; Su, G.; Torbenson, M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res., 2004, 10(24), 8421-8425. (Pubitemid 40053405)
60. Horie, Y.; Suzuki, A.; Kataoka, E.; Sasaki, T.; Hamada, K.; Sasaki, J.; Mizuno, K.; Hasegawa, G.; Kishimoto, H.; Iizuka, M.; Naito, M.; Enomoto, K.; Watanabe, S.; Mak, T.W.; Nakano, T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest., 2004, 113(12), 1774-1783. (Pubitemid 39071669)
61. Robinson, D. R.; Wu, Y.M.; Lin, S.F. The protein tyrosine kinase family of the human genome. Oncogene, 2000, 19(49), 5548-5557.
62. Schagdarsurengin, U.; Wilkens, L.; Steinemann, D.; Flemming, P.; Kreipe, H.H.; Pfeifer, G.P.; Schlegelberger, B.; Dammann, R. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene, 2003, 22(12), 1866-1871. (Pubitemid 36513145)
63. Calvisi, D.F.; Ladu, S.; Gorden, A.; Farina, M.; Conner, E.A.; Lee, J.S.; Factor, V.M.; Thorgeirsson, S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology, 2006, 130(4), 1117-1128.
64. McKillop, I.H.; Schmidt, C.M.; Cahill, P.A.; Sitzmann, J.V. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology, 1997, 26(6), 1484-1491. (Pubitemid 27520013)
65. Wentz, S.C.; Wu, H.; Yip-Schneider, M.T.; Hennig, M.; Klein, P.J.; Sebolt-Leopold, J.; Schmidt, C.M. Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice. J. Gastrointest. Surg., 2008, 12(1), 30-37.
66. Huynh, H.; Soo, K.C.; Chow, P.K.; Tran, E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol. Cancer Ther., 2007, 6(1), 138-146. (Pubitemid 46206676)
67. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer, 2005, 5(5), 341-354. (Pubitemid 40637826)
68. Bromberg, J.F. Activation of STAT proteins and growth control. Bioessays, 2001, 23(2), 161-169. (Pubitemid 32116649)
69. Yoshikawa, H.; Matsubara, K.; Qian, G.S.; Jackson, P.; Groopman, J.D.; Manning, J.E.; Harris, C.C.; Herman, J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet., 2001, 28(1), 29-35. (Pubitemid 32405812)
70. Niwa, Y.; Kanda, H.; Shikauchi, Y.; Saiura, A.; Matsubara, K.; Kitagawa, T.; Yamamoto, J.; Kubo, T.; Yoshikawa, H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene, 2005, 24(42), 6406-6417. (Pubitemid 41486474)
71. Ogata, H.; Kobayashi, T.; Chinen, T.; Takaki, H.; Sanada, T.; Minoda, Y.; Koga, K.; Takaesu, G.; Maehara, Y.; Iida, M.; Yoshimura, A. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology, 2006, 131(1), 179-193. (Pubitemid 44015756)
72. Lee, Y.H.; Yun, Y. HBx protein of hepatitis B virus activates Jak1-STAT signaling. J. Biol. Chem., 1998, 273(39), 25510-25515. (Pubitemid 28443322)
73. Bock, C.T.; Toan, N.L.; Koeberlein, B.; Song, le.H.; Chin, R.; Zentgraf, H.; Kandolf, R.; Torresi, J. Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma. Intervirology, 2008, 51(6), 432-443.
74. Miyoshi, H.; Fujie, H.; Shintani, Y.; Tsutsumi, T.; Shinzawa, S.; Makuuchi, M.; Kokudo, N.; Matsuura, Y.; Suzuki, T.; Miyamura, T.; Moriya, K.; Koike, K. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J. Hepatol., 2005, 43(5), 757-763. (Pubitemid 41414500)
75. Roberts, P.J.; Der, C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26(22), 3291-3310. (Pubitemid 46763022)
76. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64(19), 7099-7109. (Pubitemid 39331023)
77. Carlomagno, F.; Anaganti, S.; Guida, T.; Salvatore, G.; Troncone, G.; Wilhelm, S.M.; Santoro, M. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst., 2006, 98(5), 326-334. (Pubitemid 43338212)
78. Rahmani, M.; Davis, E.M.; Bauer, C.; Dent, P.; Grant, S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem., 2005, 280(42), 35217-35227. (Pubitemid 41532709)
79. Yu, C.; Bruzek, L.M.; Meng, X.W.; Gores, G.J.; Carter, C.A.; Kaufmann, S.H.; Adjei, A.A. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene, 2005, 24(46), 6861-6869. (Pubitemid 41509409)
80. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res., 2006, 66(24), 11851-11858. (Pubitemid 46094197)
81. Molhoek, K.R.; Griesemann, H.; Shu, J.; Gershenwald, J.E.; Brautigan, D.L.; Slingluff, C.L., Jr. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res., 2008, 68(11), 4392-4397.
82. Lasithiotakis, K.G.; Sinnberg, T.W.; Schittek, B.; Flaherty, K.T.; Kulms, D.; Maczey, E.; Garbe, C.; Meier, F.E. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol., 2008, 128(8), 2013-2023. (Pubitemid 352001225)
83. Strumberg, D.; Richly, H.; Hilger, R.A.; Schleucher, N.; Korfee, S.; Tewes, M.; Faghih, M.; Brendel, E.; Voliotis, D.; Haase, C.G.; Schwartz, B.; Awada, A.; Voigtmann, R.; Scheulen, M.E.; Seeber, S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol., 2005, 23(5), 965-972. (Pubitemid 46202316)
84. Abou-Alfa, G.K.; Schwartz, L.; Ricci, S.; Amadori, D.; Santoro, A.; Figer, A.; De Greve, J.; Douillard, J.Y.; Lathia, C.; Schwartz, B.; Taylor, I.; Moscovici, M.; Saltz, L.B. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol., 2006, 24(26), 4293-4300. (Pubitemid 46630787)
85. Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W.Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol., 2009, 10(1), 25-34.
86. Morimoto, M.; Numata, K.; Kondo, M.; Hidaka, H.; Takada, J.; Shibuya, A.; Miyakawa, K.; Ohkawa, S.; Okuse, C.; Tanaka, K. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma patients: a multicenter study of Kanagawa Liver Study Group. Kanzo, 2010, 51(8), 411-417 (in Japanese with English abstract).
87. Reig, M.E.; Forner, A.; De Lope, C.R.; Rimola, J.; Mestes, C.A.; Livolet, J.M.; Bruix J. In: Emergence of adverse cardiovascular events after long term sorafenib treatment for advanced hepatocellular carcinoma, Proceedings of The Liver Meeting 2009, Boston, Massachusetts, USA, October 30-November 3, 2010; Lindor, K.D., Eds.; American Association for the study of liver diseases: Virginia, USA, 2009; pp. 1080A.
88. Huether, A.; Hopfner, M.; Baradari, V.; Schuppan, D.; Scherubl, H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem. Pharmacol., 2005, 70(11), 1568-1578. (Pubitemid 41540350)
89. Goldstein, N.I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1995, 1(11), 1311-1318.
90. Fan, Z.; Lu, Y.; Wu, X.; Mendelsohn, J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem., 1994, 269(44), 27595-27602. (Pubitemid 24346592)
91. Prewett, M.; Rockwell, P.; Rockwell, R.F.; Giorgio, N.A.; Mendelsohn, J.; Scher, H.I.; Goldstein, N.I. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. Emphasis Tumor Immunol., 1996, 19(6), 419-427.
92. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer, 2001, 1(2), 118-129. (Pubitemid 33741887)
93. Zhu, A.X.; Stuart, K.; Blaszkowsky, L.S.; Muzikansky, A.; Reitberg, D.P.; Clark, J.W.; Enzinger, P.C.; Bhargava, P.; Meyerhardt, J.A.; Horgan, K.; Fuchs, C.S.; Ryan, D.P. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer, 2007, 110(3), 581-589. (Pubitemid 47106147)
94. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N. Engl. J. Med., 2004, 351(4), 337-345. (Pubitemid 38944402)
95. Asnacios, A.; Fartoux, L.; Romano, O.; Tesmoingt, C.; Louafi, S.S.; Mansoubakht, T.; Artru, P.; Poynard, T.; Rosmorduc, O.; Hebbar, M.; Taieb, J. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer, 2008, 112(12), 2733-2739. (Pubitemid 351969218)
96. Woodburn, J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther., 1999, 82(2-3), 241-250. (Pubitemid 29255919)
97. Barker, A.J.; Gibson, K.H.; Grundy, W.; Godfrey, A.A.; Barlow, J.J.; Healy, M.P.; Woodburn, J.R.; Ashton, S.E.; Curry, B.J.; Scarlett, L.; Henthorn, L.; Richards, L. Studies leading to the identification of ZD1839 (IRESSA), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett., 2001, 11(14), 1911-1914. (Pubitemid 32675316)
98. Ciardiello, F.; Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 2001, 7(10), 2958-2970. (Pubitemid 32963812)
99. Albanell, J.; Rojo, F.; Baselga, J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol., 2001, 28(5 Suppl 16), 56-66. (Pubitemid 33065111)
100. Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A.R.; Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 2000, 6(5), 2053-2063. (Pubitemid 30305105)
101. Hopfner, M.; Sutter, A.P.; Huether, A.; Schuppan, D.; Zeitz, M.; Scherubl, H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J. Hepatol., 2004, 41(6), 1008-1016. (Pubitemid 39575669)
102. Matsuo, M.; Sakurai, H.; Saiki, I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol. Cancer Ther., 2003, 2(6), 557-561.
103. O'Dwyer, P.J.; Giantonio, B.J.; Levy, D.E.; Kauh, J.S.; Fitzgerald, D.B.; Benson, A.B. 3rd. In: Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203, 2006 ASCO Annual Meeting Proceedings, Atlanta, Georgia, USA, June 2-6, 2006; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2006; pp. 213s.
104. Lopes, G.; Ho, C.K.; Liau, K.H.; Chung, A.; Cheow, P.; Chang, A.Y.; Singapore Hepatocellular Carcinoma Consortium. Gefitinib in the adjuvant treatment of hepatocellular carcinoma: A pilot study by the Singapore hepatocellular carcinoma consortium, 2010 ASCO Annual Meeting Proceedings, Chicago, Illinois, USA, June 4-8, 2010; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2010; pp. 33s.
105. Grunwald, V.; Hidalgo, M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst., 2003, 95(12), 851-867. (Pubitemid 36833877)
106. Moyer, J.D.; Barbacci, E.G.; Iwata, K.K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doty, J.; Morin, M.J.; Moyer, M.P.; Neveu, M.; Pollack, V.A.; Pustilnik, L.R.; Reynolds, M.M.; Sloan, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 1997, 57(21), 4838-4848. (Pubitemid 27468992)
107. Perez-Soler, R.; Chachoua, A.; Hammond, L.A.; Rowinsky, E.K.; Huberman, M.; Karp, D.; Rigas, J.; Clark, G.M.; Santabarbara, P.; Bonomi, P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol., 2004, 22(16), 3238-3247. (Pubitemid 41103678)
108. Philip, P.A.; Mahoney, M.R.; Allmer, C.; Thomas, J.; Pitot, H.C.; Kim, G.; Donehower, R.C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol., 2005, 23(27), 6657-6663. (Pubitemid 46190260)
109. Thomas, M.B.; Chadha, R.; Glover, K.; Wang, X.; Morris, J.; Brown, T.; Rashid, A.; Dancey, J.; Abbruzzese, J.L. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer, 2007, 110(5), 1059-1067. (Pubitemid 47312872)
110. Thomas, M.B.; Morris, J.S.; Chadha, R.; Iwasaki, M.; Kaur, H.; Lin, E.; Kaseb, A.; Glover, K.; Davila, M.; Abbruzzese, J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol., 2009, 27(6), 843-850.
111. Kaseb, A.O.; Morris, J.; Hassan. M.; Iwasaki, M.; Deaton, L.; Javle, M.M.; Garrett-Mayer, E.; Onicescu, G.; Abbruzzese, J.L.; Thomas, M.B. In: Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study, 2010 ASCO Annual Meeting Proceedings, Chicago, Illinois, USA, June 4-8, 2010; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2010; pp. 312s.
112. Hsu, C.; Kang, Y.; Yang, T.; Su, W.; Sandoval-Tan, J.; Chiou, T.; Jin, K.; Button, P.; Hsu, C.; Cheng, A. In: A phase II study of bevacizumab (B) and erlotinib (E) in combination for Asian patients (pts) with advanced/ metastatic hepatocellular carcinoma (HCC), An interim safety report, 2009 ASCO Annual Meeting Proceedings, Orland, Florida, USA, May 29-June 2, 2009; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2009; pp. 222s.
113. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov., 2007, 6(9), 734-745. (Pubitemid 47338181)
114. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J.Y.; Chu, J.Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T.C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z) -ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem., 2003, 46(7), 1116-1119. (Pubitemid 36428215)
115. Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G.; Schreck, R.E.; Abrams, T.J.; Ngai, T.J.; Lee, L.B.; Murray, L.J.; Carver, J.; Chan, E.; Moss, K.G.; Haznedar, J.O.; Sukbuntherng, J.; Blake, R.A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res., 2003, 9(1), 327-337. (Pubitemid 36109749)
116. Zhu, A.X.; Sahani, D.V.; Duda, D.G.; di Tomaso, E.; Ancukiewicz, M.; Catalano, O.A.; Sindhwani, V.; Blaszkowsky, L.S.; Yoon, S.S.; Lahdenranta, J.; Bhargava, P.; Meyerhardt, J.; Clark, J.W.; Kwak, E.L.; Hezel, A.F.; Miksad, R.; Abrams, T.A.; Enzinger, P.C.; Fuchs, C.S.; Ryan, D.P.; Jain, R.K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol., 2009, 27(18), 3027-3035.
117. Faivre, S.; Raymond, E.; Boucher, E.; Douillard, J.; Lim, H.Y.; Kim, J.S.; Zappa, M.; Lanzalone, S.; Lin, X.; Deprimo, S.; Harmon, C.; Ruiz-Garcia, A.; Lechuga, M.J.; Cheng, A.L. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol., 2009, 10(8), 794-800.
118. Koeberle, D.; Montemurro, M.; Samaras, P.; Majno, P.; Simcock, M.; Limacher, A.; Lerch, S.; Kovacs, K.; Inauen, R.; Hess, V.; Saletti, P.; Borner, M.; Roth, A.; Bodoky, G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist, 2010, 15(3), 285-292.
119. Worns, M.A.; Schuchmann, M.; Duber, C.; Otto, G.; Galle, P.R.; Weinmann, A. Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment. Oncology, 2010, 79(1-2), 85-92.
120. Presta, L.G.; Chen, H.; O'Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57(20), 4593-4599. (Pubitemid 27441066)
121. Simister, N.E.; Jacobowitz Israel, E.; Ahouse, J.C.; Story, C.M. New functions of the MHC class I-related Fc receptor, FcRn. Biochem. Soc. Trans., 1997, 25(2), 481-486. (Pubitemid 27260856)
122. Lin, Y.S.; Nguyen, C.; Mendoza, J.L.; Escandon, E.; Fei, D.; Meng, Y.G.; Modi, N.B. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther., 1999, 288(1), 371-378. (Pubitemid 29113511)
123. Kim, K.J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H.S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 1993, 362(6423), 841-844. (Pubitemid 23132159)
124. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342. (Pubitemid 38702844)
125. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355(24), 2542-2550. (Pubitemid 44917502)
126. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med., 2007, 357(26), 2666-2676.
127. Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, L.L.; Tong, R.T.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Kozin, S.V.; Mino, M.; Cohen, K.S.; Scadden, D.T.; Hartford, A.C.; Fischman, A.J.; Clark, J.W.; Ryan, D.P.; Zhu, A.X.; Blaszkowsky, L.S.; Chen, H.X.; Shellito, P.C.; Lauwers, G.Y.; Jain, R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 2004, 10(2), 145-147. (Pubitemid 38524883)
128. Finn, R.S.; Bentley, G.; Britten, C.D.; Amado, R.; Busuttil, R.W. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int., 2009, 29(2), 284-290.
129. Siegel, A.B.; Cohen, E.I.; Ocean, A.; Lehrer, D.; Goldenberg, A.; Knox, J.J.; Chen, H.; Clark-Garvey, S.; Weinberg, A.; Mandeli, J.; Christos, P.; Mazumdar, M.; Popa, E.; Brown, R.S., Jr.; Rafii, S.; Schwartz, J.D. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol., 2008, 26(18), 2992-2998.
130. Treiber, G. on behalf of the German HCC-RAD001/Bevazicumab Multicenter Study Group. In: Treatment of advanced or metastatic hepatocellular cancer (HCC), Interim analysis of a single-arm phase II study of bevacizumab and RAD001, 2010 ASCO Annual Meeting Proceedings, Chicago, Illinois, USA, June 4-8, 2010; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2010; pp. 326s.
131. Pazo Cid, R.A.; Esquerdo, G.; Puertolas, T.; Calderero, V.; Gil, I.; Lao, J.; Millastre, E.; Alvarez-Alejandro, M.; Madani, J.; Anton, A. In: Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC), 2010 ASCO Annual Meeting Proceedings, Chicago, Illinois, USA, June 4-8, 2010; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2010; e14619. Available from: http://meeting.ascopubs.org/cgi/content/abstract/28/15-suppl/e14619? maxtoshow=&hits=20&RESULTFORMAT=&fulltext= Bevacizumab+%28BVZ%29+as+second-line&searchid=1&FIRSTINDEX= 0&resourcetype=HWCIT
132. Dumont, F.J.; Staruch, M.J.; Koprak, S.L.; Melino, M.R.; Sigal, N.H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol., 1990, 144(1), 251-258. (Pubitemid 20030485)
133. Zhou, J.; Fan, J.; Wang, Z.; Wu, Z.Q.; Qiu, S.J.; Huang, X.W.; Yu, Y.; Sun, J.; Xiao, Y.S.; He, Y.F.; Wang, Y.Q.; Tang, Z.Y. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J. Gastroenterol., 2006, 12(19), 3114-3118. (Pubitemid 43811096)
134. Law, B.K. Rapamycin: an anti-cancer immunosuppressant? Crit. Rev. Oncol. Hematol., 2005, 56(1), 47-60.
135. Bjornsti, M.A.; Houghton, P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer, 2004, 4(5), 335-348. (Pubitemid 38579480)
136. Bierer, B.E.; Mattila, P.S.; Standaert, R.F.; Herzenberg, L.A.; Burakoff, S.J.; Crabtree, G.; Schreiber, S.L. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. U. S. A., 1990, 87(23), 9231-9235. (Pubitemid 120030599)
137. Brown, E.J.; Albers, M.W.; Shin, T.B.; Ichikawa, K.; Keith, C.T.; Lane, W.S.; Schreiber, S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature, 1994, 369(6483), 756-758.
138. Sabatini, D.M.; Erdjument-Bromage, H.; Lui, M.; Tempst, P.; Snyder, S.H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycindependent fashion and is homologous to yeast TORs. Cell, 1994, 78(1), 35-43. (Pubitemid 24228298)
139. Brunn, G.J.; Williams, J.; Sabers, C.; Wiederrecht, G.; Lawrence, J.C., Jr.; Abraham, R.T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO. J., 1996, 15(19), 5256-5267. (Pubitemid 26336209)
140. Brunn, G.J.; Hudson, C.C.; Sekulic, A.; Williams, J.M.; Hosoi, H.; Houghton, P.J.; Lawrence, J.C., Jr.; Abraham, R.T. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science, 1997, 277(5322), 99-101. (Pubitemid 27450655)
141. Withers, D.J.; Ouwens, D.M.; Nave, B.T.; van der Zon, G.C.; Alarcon, C.M.; Cardenas, M.E.; Heitman, J.; Maassen, J.A.; Shepherd, P.R. Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. Biochem. Biophys. Res. Commun., 1997, 241(3), 704-709. (Pubitemid 28036721)
142. Burnett, P.E.; Barrow, R.K.; Cohen, N.A.; Snyder, S.H.; Sabatini, D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4EBP1. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(4), 1432-1437. (Pubitemid 28103409)
143. Nourse, J.; Firpo, E.; Flanagan, W.M.; Coats, S.; Polyak, K.; Lee, M.H.; Massague, J.; Crabtree, G.R.; Roberts, J.M. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature, 1994, 372(6506), 570-573.
144. Law, B.K.; Chytil, A.; Dumont, N.; Hamilton, E.G.; Waltner-Law, M.E.; Aakre, M.E.; Covington, C.; Moses, H.L. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene- transformed, and human cancer cells. Mol. Cell Biol., 2002, 22(23), 8184-8198. (Pubitemid 35304052)
145. Barata, J.T.; Cardoso, A.A.; Nadler, L.M.; Boussiotis, V.A. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood, 2001, 98(5), 1524-1531.
146. Hui, I.C.; Tung, E.K.; Sze, K.M.; Ching, Y.P.; Ng, I.O. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int., 2010, 30(1), 65-75.
147. Wang, Z.; Zhou, J.; Fan, J.; Qiu, S.J.; Yu, Y.; Huang, X.W.; Tang, Z.Y. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res., 2008, 14(16), 5124-5130.
148. Semela, D.; Piguet, A.C.; Kolev, M.; Schmitter, K.; Hlushchuk, R.; Djonov, V.; Stoupis, C.; Dufour, J.F. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol., 2007, 46(5), 840-848. (Pubitemid 46529039)
149. Rizell, M.; Andersson, M.; Cahlin, C.; Hafstrom, L.; Olausson, M.; Lindner, P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int. J. Clin. Oncol., 2008, 13(1), 66-70. (Pubitemid 351326289)
150. Schoniger-Hekele, M.; Muller, C. Pilot study: rapamycin in advanced hepatocellular carcinoma. Aliment. Pharmacol. Ther., 2010, 32(6), 763-768.
151. Bhide, R.S.; Cai, Z.W.; Zhang, Y.Z.; Qian, L.; Wei, D.; Barbosa, S.; Lombardo, L.J.; Borzilleri, R.M.; Zheng, X.; Wu, L.I.; Barrish, J.C.; Kim, S.H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.; Wautlet, B.; Mortillo, S.; Jeyaseelan, R.Sr.; Kukral, D.; Hunt, J.T.; Kamath, A.; Fura, A.; Vyas, V.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Fargnoli, J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J. Med. Chem., 2006, 49(7), 2143-2146.
152. Huynh, H.; Ngo, V.C.; Fargnoli, J.; Ayers, M.; Soo, K.C.; Koong, H.N.; Thng, C.H.; Ong, H.S.; Chung, A.; Chow, P.; Pollock, P.; Byron, S.; Tran, E. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res., 2008, 14(19), 6146-6153.
153. Marathe, P.H.; Kamath, A.V.; Zhang, Y.; D'Arienzo, C.; Bhide, R.; Fargnoli, J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother. Pharmacol., 2009, 65(1), 55-66.
154. Ayers, M.; Fargnoli, J.; Lewin, A.; Wu, Q.; Platero, J.S. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res., 2007, 67(14), 6899-6906. (Pubitemid 47105537)
155. Park, J.W.; Finn, R.S.; Kim, J.S.; Karwal, M.; Li, R.K.; Ismail, F.; Thomas, M.; Harris, R.; Baudelet, C.; Walters, I.; Raoul, J.L. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res., 2011, 17(7),1973-1983.
156. Finn, R.S.; Raoul, J.; Manekas, D.; Baudelet, C.; Walters, I.B. In: Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC), An analysis of brivanib phase II data, 2010 ASCO Annual Meeting Proceedings, Chicago, Illinois, USA, June 4-8, 2010; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2010; pp. 324s.
157. Raoul, J.L.; Finn, R.S.; Kang, Y.K.; Park, J.W.; Harris, R.; Coric, V.; Donica, M.; Walters, I. In: An open-label phase II study of first- and secondline treatment with brivanib in patients with hepatocellular carcinoma (HCC), 2009 ASCO Annual Meeting Proceedings, Orland, Florida, USA, May 29-June 2, 2009; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2009; pp. 221s.
158. Yamada, Y.; Shidoji, Y.; Fukutomi, Y.; Ishikawa, T.; Kaneko, T.; Nakagama, H.; Imawari, M.; Moriwaki, H.; Muto, Y. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol. Carcinog., 1994, 10(3), 151-158. (Pubitemid 24257510)
159. Araki, H.; Shidoji, Y.; Yamada, Y.; Moriwaki, H.; Muto, Y. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem. Biophys. Res. Commun., 1995, 209(1), 66-72.
160. Nakamura, N.; Shidoji, Y.; Yamada, Y.; Hatakeyama, H.; Moriwaki, H.; Muto, Y. Induction of apoptosis by acyclic retinoid in the human hepatomaderived cell line, HuH-7. Biochem. Biophys. Res. Commun., 1995, 207(1), 382-388.
161. Nakamura, N.; Shidoji, Y.; Moriwaki, H.; Muto, Y. Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-alpha. Biochem. Biophys. Res. Commun., 1996, 219(1), 100-104. (Pubitemid 26071610)
162. Fukutomi, Y.; Omori, M.; Muto, Y.; Ninomiya, M.; Okuno, M.; Moriwaki, H. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxyl derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5). Jpn. J. Cancer Res., 1990, 81(12), 1281-1285.
163. Yasuda, I.; Shiratori, Y.; Adachi, S.; Obora, A.; Takemura, M.; Okuno, M.; Shidoji, Y.; Seishima, M.; Muto, Y.; Moriwaki, H. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J. Hepatol., 2002, 36(5), 660-671. (Pubitemid 34499404)
164. Suzui, M.; Masuda, M.; Lim, J.T.; Albanese, C.; Pestell, R.G.; Weinstein, I.B. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res., 2002, 62(14), 3997-4006. (Pubitemid 34791066)
165. Matsushima-Nishiwaki, R.; Shidoji, Y.; Nishiwaki, S.; Yamada, T.; Moriwaki, H.; Muto, Y. Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma. Mol. Cell. Endocrinol., 1996, 121(2), 179-190. (Pubitemid 26394727)
166. Matsushima-Nishiwaki, R.; Okuno, M.; Takano, Y.; Kojima, S.; Friedman, S.L.; Moriwaki, H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis, 2003, 24(8), 1353-1359. (Pubitemid 37038825)
167. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103(2), 211-225.
168. Kagawa, M.; Sano, T.; Ishibashi, N.; Hashimoto, M.; Okuno, M.; Moriwaki, H.; Suzuki, R.; Kohno, H.; Tanaka, T. An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. Carcinogenesis, 2004, 25(6), 979-985. (Pubitemid 38898636)
169. Sano, T.; Kagawa, M.; Okuno, M.; Ishibashi, N.; Hashimoto, M.; Yamamoto, M.; Suzuki, R.; Kohno, H.; Matsushima-Nishiwaki, R.; Takano, Y.; Tsurumi, H.; Kojima, S.; Friedman, S.L.; Moriwaki, H.; Tanaka, T. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr. Cancer, 2005, 51(2), 197-206. (Pubitemid 40734720)
170. Shimizu, M.; Suzui, M.; Deguchi, A.; Lim, J.T.; Weinstein, I.B. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin. Cancer Res., 2004, 10(3), 1130-1140. (Pubitemid 38198915)
171. Shao, R.X.; Otsuka, M.; Kato, N.; Taniguchi, H.; Hoshida, Y.; Moriyama, M.; Kawabe, T.; Omata, M. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology, 2005, 128(1), 86-95. (Pubitemid 40039961)
172. Muto, Y.; Moriwaki, H. Antitumor activity of vitamin A and its derivatives. J. Natl. Cancer Inst., 1984, 73(6), 1389-1393. (Pubitemid 15243582)
173. Komi, Y.; Sogabe, Y.; Ishibashi, N.; Sato, Y.; Moriwaki, H.; Shimokado, K.; Kojima, S. Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab. Invest., 2010, 90(1), 52-60.
174. Tatsukawa, H.; Sano, T.; Ishibashi, N.; Okuno, M.; Moriwaki, H.; Kojima, S. In: Novel mechanism of acyclic retinoid-induced apoptosis in hepatocellular carcinoma cells-dual induction of caspase 3 and transglutaminase dependent apoptotic pathways-, Proceedings of The Liver Meeting 2009, Boston, Massachusetts, USA, October 30-November 3, 2009; Lindor, K.D., Eds.; American Association for the study of liver diseases, Virginia, USA, 2009; pp. 860A.
175. Muto, Y.; Moriwaki, H.; Ninomiya, M.; Adachi, S.; Saito, A.; Takasaki, K.T.; Tanaka, T.; Tsurumi, K.; Okuno, M.; Tomita, E.; Nakamura, T.; Kojima, T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med., 1996, 334(24), 1561-1567. (Pubitemid 26177483)
176. Muto, Y.; Moriwaki, H.; Saito, A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N. Engl. J. Med., 1999, 340(13), 1046-1047. (Pubitemid 29157643)
177. Takai, K.; Okuno, M.; Yasuda, I.; Matsushima-Nishiwaki, R.; Uematsu, T.; Tsurumi, H.; Shiratori, Y.; Muto, Y.; Moriwaki, H. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology, 2005, 48(1), 39-45. (Pubitemid 40529209)
178. Okita, K.; Matsui, O.; Kumada, H.; Tanaka, K.; Kaneko, S.; Moriwaki, H.; Izumi, N.; Okusaka, T.; Ohashi, Y., Makuuchi, M.; Peretinoin Study Group. In: Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC), Results of a phase II/III randomized placebo-controlled trial, 2010 ASCO Annual Meeting Proceedings, Chicago, Illinois, USA, June 4-8, 2010; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2010; pp. 306s.
179. Szakacs, Z.; Beni, S.; Varga, Z.; Orfi, L.; Keri, G.; Noszal, B. Acid-base profiling of imatinib (gleevec) and its fragments. J. Med. Chem., 2005, 48(1), 249-255. (Pubitemid 40105263)
180. Cassier, P.A.; Blay, J.Y. Molecular response prediction in gastrointestinal stromal tumors. Target Oncol., 2010, 5(1), 29-37.
181. Waller, C.F. Imatinib mesylate. Recent Results Cancer Res., 2010, 184, 3-20.
182. Lin, A.Y.; Fisher, G.A.; So, S.; Tang, C.; Levitt, L. Phase II study of imatinib in unresectable hepatocellular carcinoma. Am. J. Clin. Oncol., 2008, 31(1), 84-88.
183. Eckel, F.; von Delius, S.; Mayr, M.; Dobritz, M.; Fend, F.; Hosius, C.; Schleyer, E.; Schulte-Frohlinde, E.; Schmid, R.M.; Lersch, C. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology, 2005, 69(5), 363-371. (Pubitemid 41797912)
184. Treiber, G.; Wex, T.; Malfertheiner, P. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J. Cancer Res. Clin. Oncol., 2009, 135(2), 271-281.
185. Graziadei, I.W.; Finkenstedt, A.; Stauber, R.; Trauner, M.; Mueller, C.; Vogel, W. In: Imatinib treatment for patients with advanced stage hepatocellular carcinoma: A multicenter phase II trial, 2010 ASCO Annual Meeting Proceedings, Chicago, Illinois, USA, June 4-8, 2010; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2010; e14629. Available from: http://meeting.ascopubs.org/cgi/content/abstract/28/15-suppl/e14629?maxtoshow= &hits=20&RESULTFORMAT=&fulltext=e14629&searchid= 1&FIRSTINDEX=0&resourcetype=HWCIT
186. Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Science, 2004, 304(5676), 1497-1500.
187. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350(21), 2129-2139. (Pubitemid 38637993)
188. Su, M.C.; Lien, H.C.; Jeng, Y.M. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett., 2005, 224(1), 117-121.
189. Wong, C.I.; Yap, H.L.; Lim, S.G.; Guo, J.Y.; Goh, B.C.; Lee, S.C. Lack of somatic ErbB2 tyrosine kinase domain mutations in hepatocellular carcinoma. Hepatol. Res., 2008, 38(8), 838-841.
190. Bekaii-Saab, T.; Williams, N.; Plass, C.; Calero, M.V.; Eng, C. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer, 2006, 6, 278.
191. Tsiambas, E.; Manaios, L.; Papanikolopoulos, C.; Rigopoulos, D.N.; Tsounis, D.; Karameris, A.; Soultati, A.; Koliopoulou, A.; Kravvaritis, C.; Sergentanis, T.; Patsouris, E.; Dourakis, S. Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays. Pathol. Oncol. Res., 2009, 15(3), 511-520.
192. Shao, Y.; Lin, Z.; Chen, T.; Hsu, C.; Shen, Y.; Cheng, A. In: Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy, 2010 ASCO Annual Meeting Proceedings, Chicago, Illinois, USA, June 4-8, 2010; Grunberg S.M., Eds; American Society of Clinical Oncology, Virginia, USA, 2010; pp. 316s.